Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis

被引：0
|
作者：
Baraliakos, Xenofon [1 ]
Ganz, Fabiana [2 ]
Kameda, Hideto [3 ]
Walsh, Jessica [4 ]
Jain, Manish [5 ]
D'Silva, Kristin [6 ]
Wung, Peter [6 ]
Bu, Xianwei [6 ]
Stigler, Jayne [6 ]
Van der Heijde, Desiree [6 ]
机构：
[1] Rheumazentrum Ruhrgebiet Herne, Herne, Germany
[2] AbbVie Inc, Luzern, Switzerland
[3] Toho Univ, Tokyo, Japan
[4] Univ Utah, Salt Lake City, UT USA
[5] Great Lakes Clin Trials, Chicago, IL USA
[6] AbbVie Inc, N Chicago, IL USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2022年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0414
引用
收藏
页码：825 / 827
页数：3
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF UPADACITINIB IN ANKYLOSING SPONDYLITIS. REAL WORLD DATA
    Merino Argumanez, C.
    Secada-Gomez, C.
    Vergara, C.
    Urruticoechea-Arana, A.
    Alonso Castro, S.
    Garcia-Vivar, M. L.
    Moreno, M.
    Almodovar Gonzalez, R.
    Blanco, R.
    Sanz, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1693 - 1694
  • [2] Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease-Modifying Antirheumatic Drug Use: A Post Hoc Analysis
    Deodhar, Atul
    Marzo-Ortega, Helena
    Wu, Joseph
    Wang, Cunshan
    Dina, Oluwaseyi
    Kanik, Keith S.
    Fallon, Lara
    Gensler, Lianne S.
    ACR OPEN RHEUMATOLOGY, 2023, 5 (12) : 632 - 643
  • [3] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS REFRACTORY TO BIOLOGIC THERAPY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
    Van der Heijde, D.
    Baraliakos, X.
    Sieper, J.
    Deodhar, A.
    Inman, R.
    Kameda, H.
    Zeng, X.
    Sui, Y.
    Bu, X.
    Pangan, A.
    Wung, P.
    Song, I. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 402 - 403
  • [4] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND AN INADEQUATE RESPONSE TO BIOLOGIC DMARD THERAPY: ONE-YEAR RESULTS FROM A PHASE 3 STUDY
    Baraliakos, X.
    Van der Heijde, D.
    Sieper, J.
    Inman, R.
    Kameda, H.
    Li, Y.
    Bu, X.
    Shmagel, A.
    Wung, P.
    Song, I. H.
    Deodhar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 887 - 888
  • [5] Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Prior bDMARD Treatment: Analysis of a Phase 3 Trial
    Deodhar, Atul
    Marzo-Ortega, Helena
    Wu, Joseph
    Wang, Cunshan
    Dina, Oluwaseyi
    Kanik, Keith S.
    Fallon, Lara
    Gensler, Lianne
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 840 - 843
  • [6] Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
    Baraliakos, Xenofon
    van der Heijde, Desiree
    Sieper, Joachim
    Inman, Robert D.
    Kameda, Hideto
    Li, Yihan
    Bu, Xianwei
    Shmagel, Anna
    Wung, Peter
    Song, In-Ho
    Deodhar, Atul
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [7] Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
    Xenofon Baraliakos
    Désirée van der Heijde
    Joachim Sieper
    Robert D. Inman
    Hideto Kameda
    Yihan Li
    Xianwei Bu
    Anna Shmagel
    Peter Wung
    In-Ho Song
    Atul Deodhar
    Arthritis Research & Therapy, 25
  • [8] Safety and efficacy of etanercept therapy in ankylosing spondylitis patients undergoing phacoemulsification surgery
    Kemeny-Beke, Adam
    Szekanecz, Zoltan
    Szanto, Sandor
    Bodnar, Nora
    Modis, Laszlo, Jr.
    Gesztelyi, Rudolf
    Zsuga, Judit
    Szodoray, Peter
    Berta, Andras
    RHEUMATOLOGY, 2010, 49 (11) : 2220 - 2221
  • [9] Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
    Davis, J. C.
    van der Heijde, D.
    Braun, D.
    Dougados, M.
    Clegg, D. O.
    Kivits, A.
    Fleischmann, R.
    Inmann, R.
    Ni, L.
    Lin, S.
    Tsuji, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 393 - 394
  • [10] Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
    Davis, J. C., Jr.
    van der Heijde, D. M.
    Braun, J.
    Dougados, M.
    Clegg, D. O.
    Kivitz, A. J.
    Fleischmann, R. M.
    Inman, R. D.
    Ni, L.
    Lin, S-L
    Tsuji, W. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (03) : 346 - 352
12345